Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Hepatology Self-Assessment Program

    Contains 5 Component(s), Includes Credits

    The goal of Hepatology Self-Assessment Program (HSAP) is a quick way for physicians and health professionals who diagnose and treat patients with liver disease to guide their self-assessment of medical knowledge utilizing short quizzes based on topics from the ABIM Certification/ Maintenance of Certification Exam Blueprint in Transplant Hepatology. Practice with board-style questions can help to identify knowledge gaps and link learners to resources for additional self-study when these gaps are identified.

    The goal of Hepatology Self-Assessment Program (HSAP) is a quick way for physicians and health professionals who diagnose and treat patients with liver disease to guide their self-assessment of medical knowledge utilizing short quizzes based on topics from the ABIM Certification/ Maintenance of Certification Exam Blueprint in Transplant Hepatology. Practice with board-style questions can help to identify knowledge gaps and link learners to resources for additional self-study when these gaps are identified. 

    Release Date: November 8, 2019
    Expiration Date: November 7, 2022

    Upon completion of this activity, learners will be able to: 

    1) Identify knowledge gaps and target study to fill those gaps in preparation for the ABIM Certification/Maintenance of Certification Exam in Transplant Hepatology

    2) Identify resources available through the AASLD to facilitate self-assessment in preparation for MOC examinations in Transplant Hepatology

    Hepatologists   
    Gastroenterologists       
    Nurse Practitioners        
    Physician Assistants               
    Fellows/Trainees
    Primary Care Physicians
    Family Practice Physicians
    Internal Medicine Physicians
    Medical Students

    Satisfactory completion 

    Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement. All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    Credits Offered Continuing Medical Education (CME): 2.5 AMA PRA Category 1 Credits™; Maintenance of Certification (ABIM MOC): 2.5 MOC Points

    Accreditation and Designation Statements

    Continuing Medical Education (CME):

    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABIM Maintenance of Certification (ABIM MOC): 

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

    ABP Maintenance of Certification (ABP MOC):

    Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 2 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

    Claiming CME Credits Physicians and other health care professionals seeking 2.5 AMA PRA Category 1 Credits™ for this enduring continuing medical education activity must complete an evaluation by November 7, 2022. 

    Claiming ABIM MOC Points Physicians seeking ABIM and or ABP MOC points must complete the CME and MOC evaluation by November 7, 2022. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

    MOC Points will be reported to the ABIM and ABP by the end of each month through November 2022 for individuals who successfully complete the MOC evaluation.

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The organizers and faculty have reported the following disclosures:

    Question Writers, Editors and Reviewers 

    Oren K. Fix, MD, MSc, FAASLD
    Nothing to disclose

    Heather M. Patton, MD, FAASLD
    Nothing to disclose

    Helen S. Te, MD, FAASLD
    Research Grants: Conatus Pharmaceuticals, Abbvie, Gilead Sciences
    Advisory Board: Gilead Sciences,Intercept Pharmaceuticals

    Mark W. Russo, MD, MPH, FAASLD
    Commercial Speaker's Bureau: Gilead, Abbvie,Intercept, Salix

    Katie Duggan, BA
    Staff Liaison
    Nothing to disclose

    Maintenance of Certification Committee

    Mark W. Russo, MD, MPH, FAASLD
    Chair
    Commercial Speaker's Bureau: Gilead, Abbvie,Intercept, Salix

    Raymond T. Chung, MD, FAASLD
    Board Liaison
    Research Grants: Abbvie, Gilead Sciences, Boehringer Ingelheim

    Curtis K. Argo, MD, MS, FAASLD
    Member
    Nothing to disclose

    Steven K. Herrine, MD, FAASLD
    Member
    Research Grants: Gilead, BMS, Galectin, Interecept 
    Leadership in related society: Board, Committee, Journal: ABIM - Chair, Transplant Hepatology Test Committee

    Vandana Khungar, MD, MSc
    Member
    Nothing to disclose

    Ayman A. Koteish, MD, FAASLD
    Member
    Nothing to disclose

    Smruti R. Mohanty, MD, MS
    Member
    Advisory Board: Gilead science, Abbvie, Merck, Bristol Meyers Squib and Intercept
    Leadership in related society: Board, Committee, Journal: Publications Committee, American College of Gastroenterology (2009- Present) Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology

    Heather M. Patton, MD, FAASLD
    Member
    Nothing to disclose

    K. Gautham Reddy, MD, FAASLD
    Member
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept, Gilead
    Research Grants: Merck Intercept Genfit
    Commercial Speaker's Bureau: Intercept
    Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of;

    Grace L. Su, MD, FAASLD
    Member
    Company: Management Position

    Ryan M. Taylor, MD
    Member
    Commercial Speaker's Bureau: Merck, Inc., Abbvie, Inc., Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb

    Helen S. Te, MD, FAASLD
    Member
    Research Grants: Conatus Pharmaceuticals, Abbvie, Gilead Sciences
    Advisory Board: Gilead Sciences,Intercept Pharmaceuticals

    Debra Guss, RN, NP-C, ACRN
    Associate
    Nothing to disclose

    Katie Duggan, BA
    Staff Liaison
    Nothing to disclose

  • Systematic Screening for NAFLD-Related Advanced Fibrosis in Patient with Type 2 Diabetes, Where Do We Stand?

    Contains 2 Component(s) Recorded On: 10/09/2019

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on October 9, 2019.

    The systematic screening for NAFLD is currently not recommended by the AASLD practice guidelines although the presence of type 2 diabetes is a known risk factor for the progression of NAFLD towards NASH and advanced fibrosis. This webinar will discuss the pros and cons for the systematic screening of NAFLD-related advanced fibrosis in patient with type 2 diabetes. The point of view of the hepatologist and the diabetologist will be exposed in an interactive discussion. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Cyrielle Caussy

    Dr. Cyrielle Caussy is an associate professor of nutrition and an endocrinologist at Lyon 1 University and Lyon South Hospital in Lyon, France. During her medical training she graduated her PhD at Lyon 1 University studying the epigenetic regulation of plasma triglycerides concentration involving microRNAs at the CarMen laboratory (Cardio-Metabolism, Diabetes and Nutrition). Dr Caussy’ s main field of research interests are insulin-resistance and nonalcoholic fatty liver disease (NAFLD). She completed a 2-year advanced research training at the NAFLD Research Center, University of California at San Diego directed by Dr Rohit Loomba. She now has a specific interest in non-invasive biomarkers and pathophysiology of NAFLD, especially in high risk population such as type 2 diabetes and obese patients.

    Jörn Schattenberg

    Jörn M. Schattenberg, MD received his medical degree from the University of Mainz, Germany in 2002 after studying Medicine in Mainz, Germany and Tulane University, New Orleans (US). He completed his postdoctoral training at the Albert-Einstein College of Medicine, New York, where he focused on delineating signaling pathways involved in the pathophysiology of NASH. He trained in Medicine and Gastroenterology & Hepatology at the University Medical Center Mainz and is board-certified for Internal Medicine and GI. He leads the translational NAFLD Research Program at the University Medical Center Mainz and a basic science research laboratory focusing on clinical and experimental aspects of NAFLD/NASH, the development of therapeutic intervention and novel biomarkers. He participated in the development of the German guidelines on the treatment of NASH and acts as Editorial Board Member of HEPATOLOGY and the Journal of Hepatology.

    Veeral Ajmera (Moderator)

    Dr. Veeral Ajmera is Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of California, San Diego (UCSD). He conducts clinical and translational research in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH).

    Dr. Ajmera is a member of the UCSD NAFLD Research Unit where he collaborates with a multidisciplinary team of experts on research in non-invasive biomarkers and patient factors associated with NAFLD severity and prognosis. He is a co-investigator for adult hepatology for the NIDDK-sponsored NASH Clinical Research Network and is a member of the American Association for the Study of Liver Diseases (AASLD). Dr. Ajmera also serves on the Education Committee of the AASLD. Dr. Ajmera has published widely in high impact gastroenterology and hepatology journals including GastroenterologyGut, HEPATOLOGY, Journal of HepatologyClinical Gastroenterology and HepatologyCellular and Molecular Gastroenterology and Hepatology and the American Journal of Gastroenterology. He also serves as the Medical Director of Liver Transplantation at UCSD and has a clinical emphasis on NAFLD and advanced liver disease.

  • Liquid Biopsy in Hepatocellular Carcinoma: Applications in Surveillance and Prediction of Treatment Response

    Product not yet rated Contains 2 Component(s) Recorded On: 10/02/2019

    Webinar hosted by the Hepatobiliary Neoplasia Special Interest Group on October 2, 2019.

    Liquid biopsy entails the analysis of tumor components released by cancer cells to biological fluids such as blood, saliva or cerebrospinal fluid. It has emerged as a promising source of novel biomarkers in the clinical management of patients with hepatocellular carcinoma. We will discuss the current developmental status of this technology and how it may change decision-making in patients with hepatocellular carcinoma. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Lewis R. Roberts

    Dr. Lewis R. Roberts is the Peter and Frances Georgeson Professor in Gastroenterology Cancer Research and a Consultant in the Division of Gastroenterology and Hepatology at the Mayo Clinic, where he is Director of the Hepatobiliary Neoplasia Clinic, Co-Chair of the Hepatobiliary Cancer Disease Group of Mayo Clinic Cancer Center, Co-Principal Investigator of the Mayo Specialized Program of Research Excellence (SPORE) in Hepatobiliary Cancers, Associate Director of Pre-Doctoral Programs in the Center for Clinical and Translational Sciences, and Director for Research at Mayo Clinic Alix School of Medicine. Dr. Roberts earned his medical degree from the University of Ghana Medical School, a PhD in Physiology and Biophysics from The University of Iowa, and completed postgraduate training in Internal Medicine, Gastroenterology and Hepatology, and Cancer Genetics at Mayo Clinic.

    Dr. Roberts clinical practice is focused on liver and biliary cancers. His research includes studies of the mechanisms of liver and biliary carcinogenesis; biomarkers to improve the diagnosis of liver, bile duct and pancreas cancers; and prevention, diagnosis and treatment of hepatitis and liver cancer. His research has been funded by NIH, The Robert Wood Johnson Foundation, the AGA Foundation, and The Cholangiocarcinoma Foundation. He has authored over 300 publications.

    Dr. Roberts currently serves as Deputy Editor of HEPATOLOGY and is on the Editorial Boards of Liver Cancer and Hepatic Oncology.

    Ju Dong Yang

    Dr. Yang is an academic faculty/staff physician in the Division of Digestive and Liver Diseases and Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center in Los Angeles, California, USA. He has contributed to clinical and translational research of liver cancer with over 50 scientific peer-reviewed original research articles. He has research interest in liquid biopsy and his scientific goal is to investigate an exciting area of individualized, precision medicine in the field of liver cancer. He serves as a member of Hepatobiliary Neoplasia Special Interest Group and an editorial board of HEPATOLOGY.

    John Kisiel

    My overall career goal is to reduce the burden of human suffering attributable to cancer through the early detection and treatment of pre-symptomatic disease. My primary research focus is the discovery and translational development of biomarkers for cancer detection by minimally invasive means. I lead a multidisciplinary team to integrate molecular markers, primarily methylated DNA, to noninvasively screen for cancers that are difficult to detect by currently available tools; with this effort, we hope to improve patient care and lower costs. I am a practicing gastroenterologist with clinical expertise in gastrointestinal neoplasia, inflammatory bowel disease and endoscopy.

    Our research team has an outstanding track record in the development of novel assay chemistry, specimen sampling and analyte preservation methodology in support of improved clinical or analytical sensitivity of tests to detect neoplasia. Our statistical core has developed novel methods for analysis of next-generation sequencing data and prediction methods for liquid biopsy results. Mayo Clinic is a leading clinical center of excellence with a high volume of cancer and at risk patients who are met by our outstanding clinical coordinator network. We have a close collaboration with the research and development laboratory at Exact Sciences (Madison Wisconsin USA) and are funded by the National Institutes of Health.

    Augusto Villanueva (Moderator)

    Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York). He received his medical degree from the University of Santiago de Compostela (Spain), and he is board certified in Gastroenterology and Hepatology (Spain). In 2005, he joined the Division of Liver Diseases at Mount Sinai Hospital (New York) as a research fellow and was involved in different translational research projects focused on the molecular pathogenesis of hepatocellular carcinoma (HCC). In 2008, he obtained his PhD and received the Sheila Sherlock Fellowship from EASL to join the Liver Cancer Translational Research Laboratory of the BCLC Group, Barcelona (Spain). In 2010, he became the Scientific Manager of the HEPTROMIC consortium, a research initiative funded by the European Commission aimed at identifying genomic prognostic predictors and oncogenic drivers in HCC.

    In 2013, he joined the Institute of Liver Studies at King’s College (London), as a Senior Lecturer and Consultant Hepatologist where he served as co-leader of the HCC Clinic and Multidisciplinary Tumor Board. In 2014, he started his position at the Icahn School of Medicine at Mount Sinai with the goal of developing novel minimally invasive biomarkers using liquid biopsy and studying the impact of intratumor heterogeneity in HCC. He has more than 100 publications (10,000 citations, H-index 44) including articles in N Engl J MedNat GenetNat BiotechGastroenterology, HEPATOLOGY, J HepatolJ Clin InvestOncogene, etc. He wrote more than fifteen book chapters and edited a book on resistance to targeted therapies in HCC. He served as Associate Editor for J Hepatol (2014-2019) and Liver Cancer (2012-present).

  • Overview of Transplantation for Acute on Chronic Liver Failure

    Contains 2 Component(s) Recorded On: 09/30/2019

    Webinar hosted by the Acute on Chronic Liver Failure Special Interest Group on September 30, 2019.

    In the first part of the webinar, we will provide an overview regarding the definitions of acute-on-chronic liver failure and the management of the cirrhotic patient with multi-organ system failure. In the second part, we will discuss several recent publications regarding wait list mortality and post-transplant outcomes for patients with severe acute-on-chronic liver failure. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Vinay Sundaram

    Dr. Vinay Sundaram is a transplant hepatologist at Cedars-Sinai Medical Center, where he serves as assistant medical director of liver transplantation and director of hepatology outcomes research. He has been a member of the AASLD since 2009. He is actively involved with numerous committees including the AASLD membership and mentorship committee, chair of the education subcommittee for the clinical practice special interest group.  In addition, he is on the membership and professional standards committee for UNOS. His research interests include end-stage liver disease, acute on chronic liver failure and post-transplant outcomes. He has over 100 published manuscripts and abstracts and is on the editorial board for Hepatology Communications. 

    Constantine J. Karvellas (Moderator)

    Dr. Constantine (Dean) Karvellas is an Associate Professor of Medicine (Critical Care Medicine and Gastroenterology/Hepatology) at the University of Alberta and an Adjunct Professor in the School of Public Health Sciences. He has been an attending intensivist in the E. Garner King General Systems Intensive Care Unit since 2009 and is involved with the Liver Transplant program as a Hepatologist. Dr. Karvellas is the only Canadian co-investigator in the NIH-funded United States Acute Liver Failure study group (US ALFSG). He is also a Vice Chair of the Society of Critical Care Medicine (SCCM) Liver management task force and serves as an Associate Editor for the Journal of Hepatology. Dr. Karvellas’ publications reflect his interests in acute liver failure (ALF), acute on chronic liver failure (ACLF), liver transplantation and extracorporeal liver support.

  • New Insights Into the Pathogenesis and Management of Cystic Fibrosis-Related Liver Disease

    Product not yet rated Contains 2 Component(s) Recorded On: 09/24/2019

    Webinar hosted by the Pediatric Liver Disorders Special Interest Group on September 24, 2019.

    Our understanding of liver disease pathogenesis and manifestations in cystic fibrosis is evolving, as ongoing research and clinical experience expands. This webinar will provide updates on current understanding of CLFD pathogenesis, on strategies for diagnosis and monitoring, and on management of CFLD complications. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    A. Jay Freeman

    Dr. Freeman is an Associate Professor of Pediatrics in the Gastroenterology, Hepatology and Nutrition Division at Emory University and Children’s Healthcare of Atlanta. He serves as the Director of Digestive Health for the Emory Children’s Cystic Fibrosis Program and Director of the Advanced Pancreatic Care Program at CHOA. He completed his pediatric residency at the University of Mississippi’s Batson’s Children’s Hospital and received his training in pediatric gastroenterology and hepatology at Emory University.

    As part of his clinical role Dr. Freeman oversees a dedicated CF clinic that serves patients with CF experiencing GI and liver disease including evaluation for liver transplantation. He is an active member of CFLD-NET with special interest in biomarkers and elastography as modalities to determine disease progression. Additionally, he is a member of the joint NASPGHAN-ESPGHAN committee tasked on defining and classifying CFLD, serves on the NASPGHAN Pancreas and CF committee, is the GI/Liver advisor on the CF Patient Registry-PHIs linkage project, and is a national primary investigator for the CF Foundation sponsored GALAXY Study which includes 26 sites across the United States. Most recently he was the lead author on the only manuscript that addresses the multi-disciplinary approach to pre- and post-transplant care for patients with CF undergoing liver transplantation.

    Daniel H. Leung (Moderator)

    Dr. Daniel H. Leung is an Associate Professor of Pediatrics within the Division of Gastroenterology, Hepatology, and Nutrition at Baylor College of Medicine and Director of Hepatology and Liver Transplant Medicine at Texas Children’s Hospital. He is devoted to the study and care of children with chronic fibroinflammatory liver diseases, with an emphasis on cystic fibrosis related liver disease and viral hepatitis. Dr. Leung was awarded a 3-year Developing Innovative Gastroenterology Specialty Training (DIGEST) grant by the CF Foundation in 2014 to further develop clinical and research expertise in the gastroenterological and liver care of people with CF.

    He currently serves as an investigator on the steering committee of the multi-center CF Liver Disease Network where he has focused on non-invasive measures of liver fibrosis (serum biomarkers and imaging) in children with CFLD. Dr. Leung’s academic interests include the etiopathogenesis of CFLD, novel therapies to reverse liver fibrosis or portal hypertension in CF and optimizing pre and post liver transplant outcomes of children with CF and liver disease.

    Michael R. Narkewicz (Moderator)

    Michael R. Narkewicz, MD, earned his medical degree from the University of Vermont in 1983. He completed his Pediatric Residency training at the University of Colorado School of Medicine in 1986. In 1989, he completed his Fellowship in Pediatric Gastroenterology and Nutrition at the University of Colorado School of Medicine, which also included two years of research as a Pediatric Scientist Training Program Fellow in Meudon-Bellevue, France.

    Dr. Narkewicz joined the faculty of the Department of Pediatrics at the University of Colorado School of Medicine and Children’s Hospital Colorado in 1989. He was appointed Professor of Pediatrics in 2003 and was awarded tenure in 2015. He was the Medical Director of the Pediatric Liver Center from 1998-2017 and Medical Director of the Liver Transplantation Program at The Children’s Hospital from 1998-2015. He served as the Director of the Fellowship Program in Pediatric Gastroenterology from 2005 to 2013 and as the Director of Clinical Services in Pediatric Gastroenterology from 2006-2011. He was the Associate Dean for Pediatric Clinical Affairs and Associate Medical Director for Pediatric Services for the University of Colorado School of Medicine and University of Colorado Medicine from 2011-2017. He was the Medical Director for Ambulatory Care at Children’s Hospital Colorado from 2011-2018. In 2017 he was named Executive for Strategic Provider Partnerships at Children’s Hospital Colorado.

    Dr. Narkewicz is nationally recognized for his expertise in pediatric hepatology and liver transplantation. His research interests include clinical studies in children with cystic fibrosis liver disease, pediatric chronic viral hepatitis biliary atresia, Fontan associated liver disease, hematologic and immunologic complications following pediatric liver transplantation, and clinical trials in acute liver failure and cystic fibrosis liver disease. Dr. Narkewicz is Principal Investigator of the Cystic Fibrosis Liver Disease Network leading 3 studies focused on identifying markers to predict the development of advanced CF liver disease including PUSH, ELASTIC and a proteomic study.

  • HCC Staging and Treatments

    Contains 2 Component(s) Recorded On: 09/10/2019

    Webinar hosted by the Hepatology Associates Interest Group on September 10, 2019.

    This webinar will cover Barcelona Clinic Liver Cancer (BCLC) staging in hepatocellular carcinoma. Attendees will also receive an overview of curative options of surgical resection, liver transplant, and ablative techniques and noncurative options of TACE, TARE, SBRT, and systemic chemotherapy. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Vicki Shah

    Vicki Shah PA-C, MMS received a Bachelor’s of Science in Biochemistry with minor in Mathematics from California State University, Long Beach. After completing neuroscience research at UCLA, she graduated from Midwestern University in Downers Grove, IL with a Masters in Medical Sciences and Physician Assistant Studies.

    She first started in underserved internal medicine and urgent care in Southern California. She became interested in gastroenterology after caring for her father who had esophageal cancer. She practiced in gastroenterology for five years at Carle Hospital with University of Illinois in Urbana, IL. Vicki joined Hepatology at Rush University in 2016 with a strong dedication to providing education as an instructor at the PA program, national lecturer for conferences, and APP medical advisory chair for American Liver Foundation. She is active in AASLD as a member of the Associates Committee and Associates SIG. Vicki is also on the editorial board for Clinical Liver Disease multimedia journal with AASLD and a reviewer for Fundamentals of Liver Disease.

    HoChong Gilles (Moderator)

    HoChong Gilles is a board-certified Nurse Practitioner and has been working in the hepatology field since 2001. She obtained a BS in Biology and Master’s in Nursing from Virginia Commonwealth University. She graduated with a Doctorate in Nursing Practice from the University of Virginia in 2018. Her research interests include portal hypertension and liver transplantation. She is the Clinical Program Manager for Hepatology and Liver Transplant at the McGuire Veterans Affairs Medical Center in Richmond, Virginia.

    Dr. Gilles is actively engaged in professional organizations including the American Association of the Study of Liver Diseases (AASLD). She was the immediate past Chair of the Hepatology Associates Committee is the Chair of the Hepatology Associates Special Interest Group. HoChong currently serves as the President of the Virginia Council of Nurse Practitioners.

  • Palliative Care: What It Is and When To Use It

    Contains 2 Component(s) Recorded On: 08/20/2019

    Webinar hosted by the Public Health/Health Care Delivery Special Interest Group on August 20, 2019.

    Palliative care is specialized, interdisciplinary care that can be offered at any stage of a serious illness and focuses on symptom management, advance care planning, decision-making, psychosocial support, care coordination, and continuity of care. This webinar will assist clinicians in assessing basic palliative care needs in patients with liver disease as the disease progresses, offering clinical management strategies to address needs, and referring to specialty-level palliative care. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Lissi Hansen

    Dr. Hansen is a professor of nursing at Oregon Health and Science University. She studied nursing at Sankt Luksas Stiftelsen’s School of Nursing in Hellerup, Denmark. She received her Bachelor of Science in Nursing from Washington State University and master’s and PhD from Oregon Health and Science University. Dr. Hansen is one of the few researchers who studies patients with liver diseases including hepatocellular carcinoma (HCC) and their informal caregivers. She has an extensive clinical experience with acutely and chronically ill and dying patients and have palliative care training from the Harvard Medical School Center for Palliative Care.

    Dr. Hansen successfully co-authored and published several articles on her research as a principal investigator. She continues ongoing studies with the American Cancer Society MRSG, National Palliative Care Research Center, NIH/NINR and NIH/NCI. The long-term goal of her program of research is to develop interventions to improve symptom management and palliative care for patients with liver diseases and their families.

    Arpan Patel

    Dr. Patel is a transplant-trained hepatologist and health services researcher at the David Geffen School of Medicine at UCLA. He is also a staff physician at the West Los Angeles Veterans Affairs Center. He performed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, followed by fellowship in gastroenterology at UCLA and fellowship in Transplant Hepatology at Mount Sinai.

    He is currently pursuing a PhD in Health Policy and Management at the Fielding School of Public Health at UCLA. Dr. Patel’s career goal is to ensure that patients with serious illnesses affecting the liver receive high-value care that optimizes their quality of life. His research goal is to understand ways that principles of palliative care can be integrated in management of these patients and their caregivers.

    Christopher Woodrell

    Dr. Woodrell is a health services researcher and board-certified internist and palliative care physician at the Icahn School of Medicine at Mount Sinai in New York City, where he is an appointed Assistant Professor. He is also Staff Physician within the Geriatric Research, Education and Clinical Center (GRECC) at the James J. Peters VAMC in the Bronx, NY. He received his Medical Doctorate, Internal Medicine Training, and Hospice and Palliative Medicine fellowship training at Mount Sinai.

    His career goal is to help improve quality of life experienced by people facing advanced liver disease and liver cancer. His research focus is developing and testing early palliative care interventions for people with hepatocellular carcinoma and their family caregivers. He completed undergraduate training in biochemistry at Swarthmore College in Pennsylvania.

    Mina Rakoski (Moderator)

    Mina Rakoski is a Transplant Hepatologist at Loma Linda University Health. She completed her medical education at Jefferson Medical College in Philadelphia, her residency at Cedars-Sinai Medical Center in Los Angeles and her Gastroenterology and Transplant Hepatology Fellowships at University of Michigan in Ann Arbor. During her time at University of Michigan, she attained her Master of Science in Health and Health Care Research through the Rackham Graduate School.

    Dr. Rakoski has a clinical and research interest in palliative care for patients with cirrhosis and hepatocellular carcinoma. She has a dual appointment in both Gastroenterology as well as Palliative Care at Loma Linda. She has started a hepatology palliative care clinic where she is able to provide integrated hepatology and palliative care services including in-office therapeutic paracentesis for patients with advanced liver disease. She is a co-investigator on a multicenter study funded by Patient-Centered Outcomes Research Institute (PCORI), which is investigating a novel approach of integrating palliative care into subspecialty clinics. She has written several review articles on palliative care in liver disease as well as presented on this topic at national conferences.

  • HBV Reactivation: How to Approach the Immunosuppressed Patient

    Contains 2 Component(s) Recorded On: 08/08/2019

    Webinar hosted by the Hepatitis B Special Interest Group on August 8, 2019.

    This webinar will review the latest approaches in the management of the immunosuppressed patient in the context of HBV reactivation, including screening, risk stratification and indication for antiviral treatment. The focus of management will be on both the oncologic and non-oncologic patient. The webinar will be organized as described below:

    Part 1: Management of the Cancer Patient

    Patients receiving cytotoxic chemotherapy
    Patients receiving monoclonal antibodies
    Patients undergoing hematopoietic stem cell transplant

    Part 2: Management of the Non-Cancer Patient

    Autoimmune based diseases: Rheumatologic, GI and dermatologic
    Reactivation in liver and non-liver solid organ transplantation
    HCV DAA Therapy

    We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Marina Nunez (Moderator)

    Marina Nunez, MD, PhD, is currently a Professor in the Department of Internal Medicine, sections on Infectious Diseases and on Gastroenterology at Wake Forest School of Medicine in Winston Salem, North Carolina. She received her MD and PhD from ‘Universidad de Navarra’ in Spain. She completed her Internal Medicine residency at ‘Clinica Universidad de Navarra’, and her fellowship in Infectious Diseases at Wake Forest University School of Medicine. She also obtained a degree in ‘Research Methodology and Design and Statistics in Health Sciences’. She is certified by the American Board in Internal Medicine and Infectious Diseases. She joined Wake Forest School of Medicine as faculty in 2006.

    Dr. Nunez has received several awards at her current institution for her contributions as educator, researcher and mentor. Her career has focused mainly on viral hepatitis, and she is internationally recognized for her work in HIV-co-infection. She is the author of more than 100 peer-reviewed articles, several book chapters and numerous abstracts and presentations reflecting her contribution to the field. Her expertise has led to the participation in national and international conferences, committees, and panels, as well as to the peer-review of numerous manuscripts for medical journals.

    Dr. Marina Nunez was a member of the NIH-CDC-HIVMA/IDSA Opportunistic Infections guidelines Hepatitis B Subject Group from 2010 to 2017. She currently serves on the Infectious Disease Society of America (IDSA) Standards and Practice Guidelines and on the AASLD Hepatitis B Special Interest Group's Education Subcommittee.

    Jessica Hwang

    Dr. Hwang is a professor in the Department of General Internal Medicine at The University of Texas MD Anderson Cancer Center. She has clinical and research experience in screening for and management of hepatitis B virus (HBV) in patients with cancer to facilitate early detection and interventions to reduce the risk of complications from immunosuppressive cancer therapy.

    She is a recipient of an NCI K07 Career Development Award and principal investigator of an NCI R21-funded prospective study comparing the effectiveness of widespread versus selective screening for HBV to prevent reactivation from cancer therapy; over 2000 patients were enrolled.

    She is a study chair of Southwest Oncology Group (SWOG) 1204 (PI: Scott Ramsey, MD, PhD), a national study to establish the seroprevalence of HBV, HCV, and HIV in patients with cancer at NCI Community Oncology Research Program cancer sites. She is the national PI of SWOG 1614, a multicenter randomized trial of prophylactic anti-HBV therapy in patients with HBV receiving anti-cancer therapy for solid tumors.

    Dr. Hwang is co-chair of the ASCO Provisional Clinical Opinion Committee on Hepatitis B Screening and am lead author of the panel’s 2015 updated recommendation. She is an invited member of the AASLD Hepatitis B Practice Guidelines Systematic Review and Writing Group; guideline recommendations were updated in 2015, also published guidance on HBV in 2018.

    She has published her work on screening and management of HBV in patients with cancer in Nature Reviews Gastroenterology and Hepatology, HEPATOLOGY, Journal of Clinical Oncology, Journal of Oncology Practice, among others.

    Hannah Lee

    Dr. Hannah Lee is an Assistant Professor of Medicine at Virginia Commonwealth University Medical Center in Richmond, VA in the Division of GI, Hepatology and Nutrition.

    She has a strong interest in liver cancer and viral hepatitis, particularly HBV. She was previously the Director of the Asian Pacific Liver Health Program in Boston Chinatown at Tufts Medical Center. She is currently Co-Director of the Multidisciplinary Liver Cancer Program at VCU and does both transplant and general hepatology. She is involved in multicenter studies evaluating the natural history of HBV and HCC.

    Her career has been focused on addressing health disparities in liver disease, particularly among disproportionately affected minority groups with chronic HBV. Some of her work has focused on screening and linkage to care. She has been involved in community research, education and outreach both locally and nationally in addressing liver health disparities in HBV and HCC among our various communities in the US.

    She currently serves on the AASLD Hepatitis B Special Interest Group's Leadership Steering Committee and is co-chair of the Education Subcommittee. She also serves as a committee member on the AASLD Public Policy Committee.

  • The 2018 Primary Biliary Cholangitis Practice Guidance: Highlights

    Product not yet rated Contains 2 Component(s) Recorded On: 07/25/2019

    Webinar recorded by the Cholestatic and Autoimmune Liver Diseases Special Interest Group on July 25, 2019.

    In this webinar, Drs. Marlyn Mayo and Cynthia Levy will discuss the most important recommendations included in the 2018 PBC Practice Guidance document. We will utilize a prerecorded webinar format for on-demand viewing on LiverLearning®.

    Cynthia Levy

    Cynthia Levy, MD, FAASLD is currently a Professor of Medicine in the Division of Hepatology at the University of Miami Miller School of Medicine. Dr. Levy received her MD from Universidade Federal do Rio de Janeiro, Brazil. She completed an Internal Medicine residency at University of Miami, a Gastroenterology Fellowship at Mayo Clinic, Rochester, and a Transplant Hepatology Fellowship at University of Florida, Gainesville, having received an AASLD Fellowship Award. Dr. Levy is a member of the AASLD Practice Guidelines Committee and of the ABIM Test and Policy Committee on Transplant Hepatology.  At the University of Miami, Dr. Levy is the program director for the Transplant Hepatology Fellowship program and Associate Director for the Schiff Center for Liver Diseases, where she conducts several industry-sponsored and investigator-initiated studies for cholestatic and autoimmune liver diseases.

    Marlyn Mayo

  • Early Liver Transplantation in Alcoholic Hepatitis

    Contains 2 Component(s) Recorded On: 07/24/2019

    Webinar hosted by the Alcoholic Liver Disease Special Interest Group on July 24, 2019.

    Alcoholic hepatitis has high short-term mortality with limited medical therapeutic options. Liver transplantation remains controversial for this indication given inability of these patients to meet six months of sobriety. Despite emerging data on early liver transplant as salvage therapy for severe alcoholic hepatitis, barriers remain on the acceptance of this option in the routine clinical care of these patients. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Alexandre Louvet

    Alexandre Louvet is professor of hepatology in the gastroenterology department of the University Hospital of Lille, France, headed by Prof. Philippe Mathurin. He earned his medical degree from the University of Lille. He received his PhD degree after a fellowship in the Institut Mondor de Recherche Biomédicale in Créteil, France, where he worked on the role of the endocannabinoid system in alcoholic liver disease in mice. His clinical interests include alcoholic liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma and viral hepatitis.

    He is involved in both clinical and basic research. His main topic in research is alcoholic hepatitis (natural history, treatment, disease modeling, transplantation, and pathophysiology). He has published several papers on the management of patients with severe alcoholic hepatitis. He is a member of the governing board of the French Association for the Study of the Liver (AFEF), of the editorial board of the Journal of Hepatology and a reviewer for several journals specialized in hepatology.

    Ashwani K. Singal

    Dr. Singal is an Associate Professor of Medicine at the University of South Dakota Sanford School of Medicine and Transplant Hepatologist at the Avera Transplant Institute. In addition, he also directs the hepatology elective course for the senior medical students at the Sanford Medical School and is Chief of Clinical Research Affairs at the Avera Transplant Institute. With clinical and translational research interests in alcoholic and non-alcoholic fatty liver diseases, renal injury in cirrhosis, and porphyria, Dr. Singal’s research has been funded by the American College of Gastroenterology, National Institute of Health, and pharmaceutical industry.

    He has over 160 original peer reviewed articles in national and international journals and book chapters. As an active executive member of the ACG practice parameters committee, Dr. Singal has developed practice guidelines for alcoholic liver disease and vascular disorders of the liver and currently involved in writing the guidelines on nutritional management of patients with cirrhosis. He also reviews research grants and scientific research abstracts for the AGA and AASLD. Dr. Singal is currently the Secretary and the Education subcommittee Chair of the Alcoholic Liver Disease Special Interest Group at AASLD.

    Thomas Schiano (Moderator)

    Dr. Thomas D. Schiano has a clinical background in hepatology, gastroenterology and clinical nutrition. He has expertise in the management of persons with cirrhosis and other acute/chronic liver diseases, and in caring for patients prior to and after liver transplantation. Dr. Schiano has varied clinical research interests including alcohol-related liver disease, nutritional aspects of liver disease, recurrence of disease post-liver transplantation, living donor liver transplantation, and management of the complications of cirrhosis. In addition, he is involved in the care of patients pre- and post-intestinal transplant. He is a member of the liver thrombosis program, an international referral center for adults and children with difficult to diagnose and unique blood clotting disorders affecting the liver and the intestines.

    Dr. Schiano is a UNOS-certified Liver Transplant physician, and is board certified in clinical nutrition, gastroenterology and transplant hepatology. Dr. Schiano completed fellowships in Hepatology and Liver Transplantation at The Mount Sinai Hospital, Gastroenterology at Temple University Hospital, and Clinical Nutrition at Memorial Sloan-Kettering Cancer Center. He completed a residency and chief residency in internal medicine at Maimonides Medical Center.

    Dr. Schiano is Professor of Medicine, Medical Director of Adult Liver Transplantation and Director of Clinical Hepatology at the Recanati/Miller Transplantation Institute. He is also Medical Director of the Intestinal Transplant program.